This week's tweet of the week comes from Patrick Crutcher of Chimera Research Group, who points out that if Bristol-Myers Squibb (BMY +0.52%) becomes cheap enough, Pfizer (PFE 0.73%) might be more interested in buying Bristol-Myers Squibb than it was in buying AstraZeneca (AZN +0.00%).
Bristol-Myers Squibb has seen a post-ASCO fall after investors were less than impressed with its immuno-oncology drugs. The pharma was priced at a premium, so it shouldn't be too surprising that any slip-up might result in a share-price drop.
Is Bristol-Myers Squibb a better fit for Pfizer than AstraZeneca was? Senior biotech specialist Brian Orelli and health-care analyst David Williamson think so. In the following video, they explain how Pfizer could get a better set of drug and pipeline acquiring Bristol-Myers Squibb, although Pfizer wouldn't get the tax benefit, which was a big driver for buying AstraZeneca.
Watch the video for more thoughts from the guys, including whether they think Pfizer might actually pull the trigger.
